(AOF) – Implanet announced a turnover down 20% in the fourth quarter, to 1.64 million euros, and an annual turnover for 2023 down 10% to 7.44 million euros. euros. The medtech specializing in implants intended for orthopedic surgery and in the distribution of technological medical equipment affirms that its cash flow of 0.25 million euros allows it to be financed until February 2024.
“Our annual turnover will have been impacted by the slowdown in our international activity” declares general manager Ludovic Lastennet. “2024 should be marked by the acceleration of the marketing of products resulting from the commercial partnership concluded with Sanyou Medical in June 2022” and by “the commercial launch of our Jazz range in China” “opening up a new territory for us with significant growth potential “.
A fundraising campaign will be launched on January 17, he adds, “to ensure the commercial development of our solutions and the financing of our cash flow needs for the next 12 months.” He specifies that Sanyou Medical has already committed 5 million euros
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.